Plain-English translation of NCT05935358 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing , a man-made clotting factor (called factor VIII), to see how well it helps people with severe hemophilia A control bleeding during major surgery. Patients in this study are already taking emicizumab as their regular prevention treatment, and this trial will add the medication during their scheduled surgery to give their blood extra clotting support when they need it most.
People with severe hemophilia A need extra clotting support during surgery to prevent dangerous bleeding. This trial will show doctors whether this medication works well and safely in patients who are already using emicizumab for everyday bleeding prevention.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the medication during and after your scheduled major surgery. The treatment continues every 8 to 24 hours until your wound heals well, and then for at least another 7 days to keep your clotting factor levels in a safe range. Your doctors will monitor your blood clotting ability and how well you recover from surgery.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States
Croatia
Finland
France